Trial Profile
Clinical Trial of a Selective Estrogen Receptor Modulator (raloxifene) in the treatment of cognitive deficits and psychotic symptoms of patients with schizophrenia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Raloxifene (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms CASSI
- 26 Aug 2013 New trial record